Beyond weight loss, early exploratory data suggest potential benefits including: Reductions in HbA1c (a marker of blood sugar control) in people with type 2 diabetes Improvements in lipid profiles (cholesterol and triglycerides) Reductions in liver fat, which may be relevant for metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD), though these findings are preliminary Possible cardiovascular benefits
[12] Other subtypes include malignant melanoma NOS (Not Otherwise Specified), balloon cell melanoma, malignant melanoma regressing, amelanotic melanoma and malignant melanoma in junctional naevus, among others
In comparison to other hypoglycemic drugs, it was found that SGLT2 inhibitors showed a greater efficacy than DPP4 inhibitors and similar or slightly less efficacy compared to metformin and TZDs (15,141)
Schedule Your Consultation 7690 Belair Road, Suite 1, Baltimore, MD 21236 | 410-368-0420 Frequently Asked Questions No
